Nurminen, Anssi
Jaatinen, Serafiina
Taavitsainen, Sinja
Högnäs, Gunilla
Lesluyes, Tom
Ansari-Pour, Naser
Tolonen, Teemu
Haase, Kerstin
Koskenalho, Antti
Kankainen, Matti
Jasu, Juho
Rauhala, Hanna
Kesäniemi, Jenni
Nikupaavola, Tiia
Kujala, Paula
Rinta-Kiikka, Irina
Riikonen, Jarno
Kaipia, Antti
Murtola, Teemu
Tammela, Teuvo L.
Visakorpi, Tapio
Nykter, Matti
Wedge, David C.
Van Loo, Peter
Bova, G. Steven http://orcid.org/0000-0003-1639-3104
Funding for this research was provided by:
Academy of Finland
Sigrid Juséliuksen Säätiö
CSC – IT Center for Science
Wellcome Trust
Suomen Kulttuurirahasto
Syöpäsäätiö
Medical Research Council (CC2008)
Cancer Research UK
Suomalainen Tiedeakatemia (312043)
Tampere University
Article History
Received: 13 April 2023
Accepted: 2 October 2023
First Online: 12 October 2023
Declarations
:
: The research conforms to the principles of the Helsinki Declaration. Patients provided informed consent for the study under Tampere University Hospital Ethics Committee approval R19074.
: Consent was obtained from the patients to publish clinically and scientifically relevant patient-related information included in the study. To reduce re-identification risk, some of the reported clinical data has been reduced in specificity.
: G. Steven Bova certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (e.g., employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Naser Ansari-Pour, Kerstin Haase, Gunilla Högnäs, Serafiina Jaatinen, Juho Jasu, Antti Kaipia, Matti Kankainen, Antti Koskenalho, Jenni Kesäniemi, Tiia Nikupaavola, Paula Kujala, Tom Lesluyes, Anssi Nurminen, Hanna Rauhala, Jarno Riikonen, Irina Rinta-Kiikka, Sinja Taavitsainen, Teemu Tolonen, Peter Van Loo, Tapio Visakorpi, and David Wedge have no conflict of interest disclosures. Teemu J. Murtola has received honoraria from Astellas, Janssen, Novartis, and Sanofi; has received travel and accommodation expenses from Sanofi and Pfizer; reports patents, royalties, and other intellectual property from Arocell; reports stock and other ownership interests in Arocell; and has received research funding from Arocell. Teuvo Tammela has received research funding from Finnish Cancer Society and Sigrid Juselius Foundation and has been an investigator in studies sponsored by Bayer, Astellas, Orion Pharma, and Pfizer. Bova and Nykter report intellectual property for Differential Subclone Eradication and Resistance (DSER) analysis [CitationRef removed]. Bova also reports speaker’s fees from Brupbacher Foundation, Sanofi Aventis, and Astellas Pharma.